Michael Posternak, MD.Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Psilocybin is inching its way toward FDA approval in depression, but will this trial from the New England Journal of Medicine help it along or set it back?
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.